MP0420

DRUG2 trials

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID)

Conditions

COVID-19Covid19

Phase 3

ACTIV-3: Therapeutics for Inpatients With COVID-19

CompletedNCT04501978

National Institute of Allergy and Infectious Diseases (NIAID)Covid19

Start: 2020-08-04End: 2023-07-14Updated: 2023-08-25

MP0420 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)

CompletedNCT05780463

National Institute of Allergy and Infectious Diseases (NIAID)COVID-19

Start: 2021-06-11End: 2023-06-08Updated: 2024-02-05

Related Papers

Long-term outcomes of passive immunotherapy for COVID-19: a pooled analysis of a large multinational platform randomized clinical trial

Clinical Microbiology and Infection2025-02-062 citations

P-1904. The Interaction of Serum Biomarkers and Lymphopenia on Pulmonary COVID-19 Illness Progression in Hospitalized Patients

Open Forum Infectious Diseases2025-01-29

Effect of Neutralizing Monoclonal Antibody Treatment on Early Trajectories of Virologic and Immunologic Biomarkers in Patients Hospitalized With COVID-19

The Journal of Infectious Diseases2023-11-094 citations

Efficacy and Safety of Ensovibep for Adults Hospitalized With COVID-19 : A Randomized Controlled Trial.

2022-08-0922 citations

Tixagevimab-cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase 3 trial.

2022-07-0896 citations

Efficacy and safety of intramuscular administration of tixagevimab-cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial.

2022-06-07173 citations

RAGE has potential pathogenetic and prognostic value in nonintubated hospitalized patients with COVID-19

JCI Insight2022-03-1727 citations

The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in nonhuman primates and has an extended half-life in humans

Science Translational Medicine2022-01-25208 citations

Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial.

2021-12-23173 citations

Responses to a Neutralizing Monoclonal Antibody for Hospitalized Patients With COVID-19 According to Baseline Antibody and Antigen Levels : A Randomized Controlled Trial.

2021-12-2169 citations

A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19

New England Journal of Medicine2020-12-22456 citations